Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 30MEQ versus MAGNESIUM SULFATE.
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 30MEQ versus MAGNESIUM SULFATE.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides calories and serves as a source of glucose, which is metabolized to carbon dioxide and water, yielding energy. Sodium and chloride are major electrolytes that maintain osmolality and acid-base balance. Potassium is essential for nerve conduction, muscle contraction, and maintaining intracellular tonicity.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous infusion; dose determined by individual patient requirements, fluid and electrolyte status, serum potassium concentration, and acid-base balance; typical adult rate: 100-200 mL/hour (up to 2 L/day) as maintenance fluid.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Glucose: 1.5–2 hours (endogenous); sodium and potassium follow body homeostatic regulation with no defined half-life in isolation.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Renal: >95% as free glucose, sodium, and potassium. Biliary/fecal: <5%.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte